miR-155 regulative network in FLT3 mutated acute myeloid leukemia

被引:22
|
作者
Salemi, Domenico [1 ]
Cammarata, Giuseppe [2 ]
Agueli, Cecilia [1 ]
Augugliaro, Luigi [3 ]
Corrado, Chiara [5 ]
Bica, Maria Grazia [1 ]
Raimondo, Stefania [5 ]
Marfia, Anna [1 ]
Randazzo, Valentina [1 ]
Dragotto, Paola [1 ]
Di Raimondo, Francesco [4 ]
Alessandro, Riccardo [5 ]
Fabbiano, Francesco [1 ]
Santoro, Alessandra [1 ]
机构
[1] AO Osped Riuniti Villa Sofia Cervello, Div Ematol Con UTMO, Palermo, Italy
[2] IBIM CNR, Palermo, Italy
[3] Univ Palermo, Dipartimento Sci Stat & Matemat Silvio Vianelli, I-90133 Palermo, Italy
[4] PO Ferrarotto Catania, Div Ematol, Catania, Italy
[5] Dipartimento Biopatol & Biotecnol Med & Forensi, Sez Biol & Genet, Palermo, Italy
关键词
Network; MicroRNA; AML; INTERNAL TANDEM DUPLICATION; MICRORNA EXPRESSION PROFILES; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-GROWTH; DIFFERENTIATION; TARGET; IDENTIFICATION; PROLIFERATION; SUPPRESSION;
D O I
10.1016/j.leukres.2015.04.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Acute myeloid leukemia (AML) represents a heterogeneous disorder with recurrent chromosomal alterations and molecular abnormalities. Among AML with normal karyotype (NK-AML) FLT3 activating mutation, internal tandem duplication (FLT3-ITD), is present in about 30% of patients, conferring unfavorable outcome. Our previous data demonstrated specific up-regulation of miR-155 in FLT3-ITD+ AML. miR-155 is known to be directly implicated in normal hematopoiesis and in some pathologies such as myeloid hyperplasia and acute lymphoblastic leukemia. Methods and results: To investigate about the potential influence of miR-155 de-regulation in FLT3-mutated AML we generated a transcription factors regulatory network and combined this with data from multiple sources that predict miR-155 interactions. From these analyses, we derived a sub-network, called "miR-155 module" that describes functional relationship among miR-155 and transcription factorsin FLT3-mutated AML. We found that "miR-155 module" is characterized by the presence of six transcription factors as central hubs: four miR-155 regulators (JUN, RUNX1, FOSb, JUNB) and two targets of miR-155 (SPI1, CEBPB) all known to be "master" genes of myelopoiesis. We found, in FLT3-mutated AML, a significant down-regulation of miR-155 target genes CEBPB and SPI1 and up-regulation of miR-155 regulator genes JUN and RUNX1. We also showed that PKC412-related FLT3 inhibition, in MV4-11 cell line, causes down-regulation of miR-155 and increased level of mRNA and protein of miR-155 target SPI1. We showed in experiments of miR-155 mimic in K562 cell line, a high increase of miR-155 and an inverse correlation with the mRNA levels of its targets SPI1 and CEBPB. Moreover silencing of miR-155 in primary AMLs causes mRNA up-regulation of its target SPI1 and CEBPB. Conclusion: Our results suggest that activating mutation of FLT3 in AML can lead, through the induction of JUN, to an increased expression of miR-155, which then causes down-regulation of SPI1 and CEBPB and consequently may causes block of myeloid differentiation. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:883 / 896
页数:14
相关论文
共 50 条
  • [1] MIR-155 REGULATIVE NETWORK IN FLT3 MUTATED ACUTE MYELOID LEUKEMIA
    Santoro, A.
    Cammarata, G.
    Salemi, D.
    Agueli, C.
    Augugliaro, L.
    Bica, M.
    Marfia, A.
    Scavo, E.
    La Rosa, M.
    Messana, F.
    Pagano, M.
    Dragotto, P.
    Onorati, R.
    Longo, G.
    Mitra, E.
    Di Raimondo, F.
    Fabbiano, F.
    HAEMATOLOGICA, 2012, 97 : 15 - 16
  • [2] Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Ramasamy Santhanam
    Jason G Harb
    David M Lucas
    Joshua J Oaks
    Christopher J Hickey
    Li Pan
    A Douglas Kinghorn
    Michael A Caligiuri
    Danilo Perrotti
    John C Byrd
    Ramiro Garzon
    Michael R Grever
    Guido Marcucci
    Journal of Hematology & Oncology, 6
  • [3] Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Alachkar, Houda
    Santhanam, Ramasamy
    Harb, Jason G.
    Lucas, David M.
    Oaks, Joshua J.
    Hickey, Christopher J.
    Pan, Li
    Kinghorn, A. Douglas
    Caligiuri, Michael A.
    Perrotti, Danilo
    Byrd, John C.
    Garzon, Ramiro
    Grever, Michael R.
    Marcucci, Guido
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [4] FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
    Naval Daver
    Sangeetha Venugopal
    Farhad Ravandi
    Blood Cancer Journal, 11
  • [5] FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
    Daver, Naval
    Venugopal, Sangeetha
    Ravandi, Farhad
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [6] The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
    Fathi, Amir T.
    Chen, Yi-Bin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 330 - 336
  • [7] Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
    Burnett, Alan K.
    Russell, Nigel H.
    Hills, Robert K.
    BLOOD, 2016, 128 (03) : 449 - 452
  • [8] Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
    Arnan Sangerman, Montserrat
    Fernandez Moreno, Ainhoa
    Garcia Quintana, Antonio
    Garcia-Vidal, Carolina
    Olave Rubio, Maria Teresa
    Tormo Diaz, Maria Del Mar
    Vendranas, Meritxell
    Rodriguez Macias, Gabriela
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 203 - 214
  • [9] Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia The Case for Total Therapy
    Perl, Alexander E.
    Pratz, Keith W.
    CANCER JOURNAL, 2022, 28 (01): : 14 - 20
  • [10] miR-155 in Acute Myeloid Leukemia: Not Merely a Prognostic Marker?
    Joyce, Cailin E.
    Novina, Carl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2219 - 2221